{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:45:23Z","timestamp":1792896323587,"version":"4.5.0"},"reference-count":81,"publisher":"Society for Neuroscience","issue":"6","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":217,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"HHS | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH107615"],"award-info":[{"award-number":["MH107615"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"HHS | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH086828"],"award-info":[{"award-number":["MH086828"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"HHS | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH086828"],"award-info":[{"award-number":["MH086828"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"name":"veterans administration","award":["1I01BX004062"],"award-info":[{"award-number":["1I01BX004062"]}],"id":[{"id":"https:\/\/ror.org\/006ym5897","id-type":"ROR","asserted-by":"crossref"}]},{"name":"veterans administration","award":["101BX003631"],"award-info":[{"award-number":["101BX003631"]}],"id":[{"id":"https:\/\/ror.org\/006ym5897","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Brain and Research Foundation","award":["26826"],"award-info":[{"award-number":["26826"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Neurosci."],"published-print":{"date-parts":[[2023,2,8]]},"abstract":"<jats:p>\n                    Ketamine is a well-characterized NMDA receptor (NMDAR) antagonist, although the relevance of this pharmacology to its rapid (within hours of administration) antidepressant actions, which depend on mechanisms convergent with strengthening of excitatory synapses, is unclear. Activation of synaptic NMDARs is necessary for the induction of canonical long-term potentiation (LTP) leading to a sustained expression of increased synaptic strength. We tested the hypothesis that induction of rapid antidepressant effects requires NMDAR activation, by using behavioral pharmacology, western blot quantification of hippocampal synaptoneurosomal protein levels, and\n                    <jats:italic>ex vivo<\/jats:italic>\n                    hippocampal slice electrophysiology in male mice. We found that ketamine exerts an inverted U-shaped dose-response in antidepressant-sensitive behavioral tests, suggesting that an excessive NMDAR inhibition can prevent ketamine's antidepressant effects. Ketamine's actions to induce antidepressant-like behavioral effects, up-regulation of hippocampal AMPAR subunits GluA1 and GluA2, as well as metaplasticity measured\n                    <jats:italic>ex vivo<\/jats:italic>\n                    using electrically-stimulated LTP, were abolished by pretreatment with other non-antidepressant NMDAR antagonists, including MK-801 and CPP. Similarly, the antidepressant-like actions of other putative rapid-acting antidepressant drugs (\n                    <jats:italic>2R,6R<\/jats:italic>\n                    )-hydroxynorketamine (ketamine metabolite), MRK-016 (GABA\n                    <jats:sub>A<\/jats:sub>\n                    \u03b15 negative allosteric modulator), and LY341495 (mGlu\n                    <jats:sub>2\/3<\/jats:sub>\n                    receptor antagonist) were blocked by NMDAR inhibition. Ketamine acted synergistically with an NMDAR positive allosteric modulator to exert antidepressant-like behavioral effects and activation of the NMDAR subunit GluN2A was necessary and sufficient for such relevant effects. We conclude rapid-acting antidepressant compounds share a common downstream NMDAR-activation dependent effector mechanism, despite variation in initial pharmacological targets. Promoting NMDAR signaling or other approaches that enhance NMDAR-dependent LTP-like synaptic potentiation may be an effective antidepressant strategy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>SIGNIFICANCE STATEMENT<\/jats:bold>\n                    The anesthetic and antidepressant drug ketamine is well-characterized as an NMDA receptor (NMDAR) antagonist; though, the relevance and full impact of this pharmacology to its antidepressant actions is unclear. We found that NMDAR activation, which occurs downstream of their initial actions, is necessary for the beneficial effects of ketamine and several other putative antidepressant compounds. As such, promoting NMDAR signaling, or other approaches that enhance NMDAR-dependent long-term potentiation (LTP)-like synaptic potentiation\n                    <jats:italic>in vivo<\/jats:italic>\n                    may be an effective antidepressant strategy directly, or acting synergistically with other drug or interventional treatments.\n                  <\/jats:p>","DOI":"10.1523\/jneurosci.1316-22.2022","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T13:50:54Z","timestamp":1672753854000},"page":"1038-1050","source":"Crossref","is-referenced-by-count":116,"title":["NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine"],"prefix":"10.1523","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-8648","authenticated-orcid":false,"given":"Panos","family":"Zanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1959-6724","authenticated-orcid":false,"given":"Kyle A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polymnia","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixiong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"393","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"2023041803554290000_43.6.1038.1","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-020-00627-z"},{"key":"2023041803554290000_43.6.1038.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1983.tb11031.x"},{"key":"2023041803554290000_43.6.1038.3","doi-asserted-by":"publisher","DOI":"10.1038\/nature10130"},{"key":"2023041803554290000_43.6.1038.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00230-9"},{"key":"2023041803554290000_43.6.1038.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.06.089"},{"key":"2023041803554290000_43.6.1038.6","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.205"},{"key":"2023041803554290000_43.6.1038.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119707"},{"key":"2023041803554290000_43.6.1038.8","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.246"},{"key":"2023041803554290000_43.6.1038.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2015.09.004"},{"key":"2023041803554290000_43.6.1038.10","unstructured":"Cerecor (2016) Cerecor reports top-line data from CERC-301 phase 2 study for major depressive disorder. Rockville: Cerecor, Inc."},{"key":"2023041803554290000_43.6.1038.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2003.10.009"},{"key":"2023041803554290000_43.6.1038.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.11.006"},{"key":"2023041803554290000_43.6.1038.13","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2016.34"},{"key":"2023041803554290000_43.6.1038.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915059107"},{"key":"2023041803554290000_43.6.1038.15","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3739"},{"key":"2023041803554290000_43.6.1038.16","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy101"},{"key":"2023041803554290000_43.6.1038.17","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2014.16.1\/rduman"},{"key":"2023041803554290000_43.6.1038.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)01390-5"},{"key":"2023041803554290000_43.6.1038.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0256-5"},{"key":"2023041803554290000_43.6.1038.20","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.112"},{"key":"2023041803554290000_43.6.1038.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1814709116"},{"key":"2023041803554290000_43.6.1038.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-022-01146-x"},{"key":"2023041803554290000_43.6.1038.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2020.11.020"},{"key":"2023041803554290000_43.6.1038.24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010617-052811"},{"key":"2023041803554290000_43.6.1038.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2015.03.019"},{"key":"2023041803554290000_43.6.1038.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114892"},{"key":"2023041803554290000_43.6.1038.27","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.9b00493"},{"key":"2023041803554290000_43.6.1038.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.10.025"},{"key":"2023041803554290000_43.6.1038.29","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31825d70d6"},{"key":"2023041803554290000_43.6.1038.30","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2022.06.016","article-title":"Nitrous oxide, a rapid antidepressant, has ketamine-like effects on excitatory transmission in adult hippocampus","volume":"92","author":"Izumi","year":"2022","journal-title":"Biol Psychiatry"},{"key":"2023041803554290000_43.6.1038.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2020.05.015"},{"key":"2023041803554290000_43.6.1038.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01411-4"},{"key":"2023041803554290000_43.6.1038.33","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx096"},{"key":"2023041803554290000_43.6.1038.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112378"},{"key":"2023041803554290000_43.6.1038.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-021-00868-8"},{"key":"2023041803554290000_43.6.1038.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.02.005"},{"key":"2023041803554290000_43.6.1038.37","first-page":"737","article-title":"CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo","volume":"240","author":"Lehmann","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"2023041803554290000_43.6.1038.38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1190287"},{"key":"2023041803554290000_43.6.1038.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1816071116"},{"key":"2023041803554290000_43.6.1038.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.05.028"},{"key":"2023041803554290000_43.6.1038.41","doi-asserted-by":"crossref","unstructured":"Miller OH , Grabole N , Wells I , Hall BJ (2018) Genome-wide translating mRNA analysis following ketamine reveals novel targets for antidepressant treatment. bioRxiv 254904.","DOI":"10.1101\/254904"},{"key":"2023041803554290000_43.6.1038.42","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997"},{"key":"2023041803554290000_43.6.1038.43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-7-123"},{"key":"2023041803554290000_43.6.1038.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.06.022"},{"key":"2023041803554290000_43.6.1038.45","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3504"},{"key":"2023041803554290000_43.6.1038.46","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000259"},{"key":"2023041803554290000_43.6.1038.47","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa025"},{"key":"2023041803554290000_43.6.1038.48","unstructured":"Paterson B , Fraser H , Wang C , Marcus R (2015) A randomized, double- blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment. In: National network of depression centers annual conference. Ann Arbor: Michigan."},{"key":"2023041803554290000_43.6.1038.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2017.10.020"},{"key":"2023041803554290000_43.6.1038.50","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31818a6cea"},{"key":"2023041803554290000_43.6.1038.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.02.033"},{"key":"2023041803554290000_43.6.1038.52","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.36"},{"key":"2023041803554290000_43.6.1038.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0443-3"},{"key":"2023041803554290000_43.6.1038.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109153"},{"key":"2023041803554290000_43.6.1038.55","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2013.130"},{"key":"2023041803554290000_43.6.1038.56","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2016.224"},{"key":"2023041803554290000_43.6.1038.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04993-7"},{"key":"2023041803554290000_43.6.1038.58","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m08252"},{"key":"2023041803554290000_43.6.1038.59","doi-asserted-by":"publisher","DOI":"10.1038\/nature22084"},{"key":"2023041803554290000_43.6.1038.60","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01422-1"},{"key":"2023041803554290000_43.6.1038.61","doi-asserted-by":"publisher","DOI":"10.1124\/pr.109.002451"},{"key":"2023041803554290000_43.6.1038.62","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biopsych.2021.11.024","article-title":"Negative allosteric modulation of gamma-aminobutyric acid a receptors at alpha5 subunit-containing benzodiazepine sites reverses stress-induced anhedonia and weakened synaptic function in mice","volume":"92","author":"Troppoli","year":"2021","journal-title":"Biol Psychiatry"},{"key":"2023041803554290000_43.6.1038.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.04.013"},{"key":"2023041803554290000_43.6.1038.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2011.08.012"},{"key":"2023041803554290000_43.6.1038.65","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2018.00008"},{"key":"2023041803554290000_43.6.1038.66","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000431"},{"key":"2023041803554290000_43.6.1038.67","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.233627"},{"key":"2023041803554290000_43.6.1038.68","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06118-4"},{"key":"2023041803554290000_43.6.1038.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2018.10.005"},{"key":"2023041803554290000_43.6.1038.70","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0390-7"},{"key":"2023041803554290000_43.6.1038.71","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.225664"},{"key":"2023041803554290000_43.6.1038.72","doi-asserted-by":"publisher","DOI":"10.1038\/nature17998"},{"key":"2023041803554290000_43.6.1038.73","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0285-16.2017"},{"key":"2023041803554290000_43.6.1038.74","doi-asserted-by":"publisher","DOI":"10.1038\/nature22085"},{"key":"2023041803554290000_43.6.1038.75","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0492-x"},{"key":"2023041803554290000_43.6.1038.76","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.015198"},{"key":"2023041803554290000_43.6.1038.77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819540116"},{"key":"2023041803554290000_43.6.1038.78","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.153"},{"key":"2023041803554290000_43.6.1038.79","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"2023041803554290000_43.6.1038.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.10.019"},{"key":"2023041803554290000_43.6.1038.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2021.173228"}],"container-title":["The Journal of Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/JNEUROSCI.1316-22.2022","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/JNEUROSCI.1316-22.2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T09:16:24Z","timestamp":1681809384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jneurosci.org\/lookup\/doi\/10.1523\/JNEUROSCI.1316-22.2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":81,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,2,8]]},"published-print":{"date-parts":[[2023,2,8]]}},"alternative-id":["10.1523\/JNEUROSCI.1316-22.2022"],"URL":"https:\/\/doi.org\/10.1523\/jneurosci.1316-22.2022","relation":{},"ISSN":["0270-6474","1529-2401"],"issn-type":[{"value":"0270-6474","type":"print"},{"value":"1529-2401","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]}}}